Dr. Guminski on 16-Month Follow-Up With Cemiplimab in mCSCC

Alexander Guminski, MD, PhD
Published: Thursday, Aug 29, 2019



Alexander Guminski, MD, PhD, medical oncologist, Royal North Shore Hospital, University of Sydney, discusses the 16-month follow-up results of a phase II trial evaluating cemiplimab (Libtayo) in patients with metastatic cutaneous squamous cell carcinoma.

In a primary analysis reported in October 2017, cemiplimab, a human monoclonal anti-PD-1 agent, demonstrated significant antitumor activity, response rates, and promising safety. In the trial, 59 patients were given 3 mg/kg of cemiplimab intravenously every 2 weeks. Tumors were measured every 8 weeks to evaluate overall response rate (ORR), which served as the primary endpoint of the trial. More than half the patients had one or more prior lines of systemic treatment, while three-fourths of patients had distant visceral metastatic disease.

At a median follow-up of 16 months, Guminski reports that there was slight improvement in ORR as the data has matured. Specifically, an ORR of 49% was reported, with 17% of that group achieving a complete response to the treatment.
SELECTED
LANGUAGE


Alexander Guminski, MD, PhD, medical oncologist, Royal North Shore Hospital, University of Sydney, discusses the 16-month follow-up results of a phase II trial evaluating cemiplimab (Libtayo) in patients with metastatic cutaneous squamous cell carcinoma.

In a primary analysis reported in October 2017, cemiplimab, a human monoclonal anti-PD-1 agent, demonstrated significant antitumor activity, response rates, and promising safety. In the trial, 59 patients were given 3 mg/kg of cemiplimab intravenously every 2 weeks. Tumors were measured every 8 weeks to evaluate overall response rate (ORR), which served as the primary endpoint of the trial. More than half the patients had one or more prior lines of systemic treatment, while three-fourths of patients had distant visceral metastatic disease.

At a median follow-up of 16 months, Guminski reports that there was slight improvement in ORR as the data has matured. Specifically, an ORR of 49% was reported, with 17% of that group achieving a complete response to the treatment.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20202.0
Publication Bottom Border
Border Publication
x